Additionally, it enhances the sensitivity of NSCLC to gefitinib, an EGFR-T790M inhibitor, suggesting its potential as a therapeutic target and diagnostic marker for NSCLC [61]. The gene discussed is EGFR; the disease is non-small cell lung carcinoma.